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Background: The use of positron emission tomography-computed tomography (PET/CT) for the preoperative
staging of patients with colon and rectal cancer has increased steadily over the last decade. The aim of this study
was to evaluate the effect of PET/CT on the preoperative staging and clinical management of patients with
colorectal cancer.
Methods: Between December 2010 and February 2012, 64 consecutive patients with colorectal cancer were
evaluated with both PET/CT scans and conventional preoperative imaging studies. We prospectively recorded the
medical reports of these patients. The PET/CT findings were compared with conventional imaging studies and the
rate of over-staging or down-staging and changes in clinical management were evaluated. The correlation of the
PET/CT with the conventional imaging was compared by a kappa agreement coefficient. Differences in the
accuracy for N and T staging were assessed by χ2 and related-samples marginal homogeneity tests.
Results: Thirty-nine (60.9%) patients had rectal cancer and 25 (39.1%) had colon cancer. Based on PET/CT,
additional lesions were found in 6 (9.4%) of the patients: hilar and paratracheal lesions in 4 patients, hepatic in 1
and supraclavicular in 1 patient. In four of six patients, detailed imaging studies or biopsies revealed chronic
inflammatory changes. Hepatic and supraclavicular involvement was confirmed in two patients. Therefore, the false
positivity rate of PET/CT was 6.25%. Based on the additional PET/CT, 2 (3.2%) patients had a change in surgical
management. A chemotherapy regimen was administered to the patient with a 1.5 cm hepatic metastasis near the
right hepatic vein; for another patient with an identified supraclavicular lymph node metastasis, a simultaneous
excision was performed.
Conclusions: Routine use of PET/CT for preoperative staging did not impact disease management for 96.8% of our
patients. The results of our study conclude that PET/CT should not be routinely used for primary staging of
colorectal cancer. More studies are required for identifying the subgroup of patients who might benefit from a PET/
CT in their initial staging.
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Colorectal malignancies are the third most common
cancer and a common cause of cancer related death [1].
Accurate preoperative staging of colorectal carcinoma
(CRC) is essential for evaluating the expected prognosis
and providing the optimal treatment strategy [2]. The
depth of invasion, occurrence of lymph node metastases
and distant metastases are the main factors that affect
the prognosis of the patient [3]. Preoperative assessment
and staging of colorectal cancer is often problematic. A
colonoscopy is a well-known procedure for inspection of
the colon, but this procedure does not provide sufficient
evidence about the depth of the tumor, lymph node in-
volvement and distant metastases [4]. Although techni-
cal refinements have provided better quality for
conventional imaging (CI) studies such as multi detector
computed tomography (MDCT) and magnetic reso-
nance imaging (MRI), complete correct preoperative
staging has not yet been obtained. A recent study
showed that the overall accuracy of MDCT was 86% in
T staging and 84% in N staging [5]; another study
reported that MRI provided an 81% overall agreement
with histological findings for the T and N stages [6].
The use of 18 F-fluorodeoxyglucose-positron emis-
sion tomography/computed tomography (PET/CT) has
allowed for better staging and resulted in clinical man-
agement variations when applied to a number of tumors
[7,8]. Currently, PET/CT is recommended only for the
assessment of the suspected recurrence of CRC and in
pre-operative staging prior to metastasectomy. Further-
more, the clinical opinion on the role of PET/CT in the
routine management of primary colon cancer varies.
Some investigators suggest that in certain clinical cir-
cumstances like the initial staging of primary rectal can-
cer, this method is going to be considered as part of the
standard preoperative assessment in the near future [9].
The aim of this study was to prospectively evaluate the
effect of PET/CT on patients with primary colorectal
cancer, including an assessment of the stage and of clini-
cal management planning.
Methods
This study had been approved by the Bezmialem
Vakif University Ethical Committee (Number: B.30.2.
BAV.0.05.05/262), and we obtained written informed
consent from all patients included in the study.
Between December 2010 and February 2012, consecu-
tive patients with currently diagnosed colorectal cancer
in our tertiary hospital were included in the study. In ad-
dition to CI studies, PET/CT was performed on these
consecutive patients, and all data were prospectively en-
tered into a database. All patients’ diagnoses were con-
firmed by histo-pathology before they were enrolled in
the study. If the patients were classified as having StageII or III rectal carcinoma, they had been referred for
neo-adjuvant therapy. All PET/CT scans were performed
before preoperative chemo-radiotherapy.
Patients were excluded if preoperative CI studies or
PET/CT was not performed at our institution, if the pa-
tients had a recurrent disease or if the patients were un-
willing to participate in the study.
The CI modalities included an examination with
abdomino-pelvic MDCT and MRI.
All preoperative MDCT studies were performed using an
MDCT scanner with 64 parallel detector rows (Toshiba
Aquilion 64, Toshiba Medical Systems Corp., Tokyo, Japan).
Nonionic intravenous contrast material (Omnipaque 300,
Amersham Health, Princeton NJ, USA) was administered
at a dose of 2 mL/kg up to a maximum of 180 mL.
MRI was performed with a 1.5 T MRI system (Magne-
tomAvanto, Siemens Healthcare, Erlangen, Germany)
with a phased-array coil. Either gadodiamide (Omniscan,
Amersham Health) or gadobutrol (Gadovist, Schering)
was used as the contrast agent.
PET/CT scans were acquired on a Siemens Biograph
16 PET/CT System (Siemens medical solutions, Knox-
ville, TN) at least one hour after intravenous injection of
18 F-fluorodeoxyglucose (FDG). All patients fasted for
six hours prior to the study, but were encouraged to
drink water. Patients also received bowel preparation
prior to the procedure. All PET/CT images were inter-
preted by one nuclear medicine specialist prior to sur-
gery. The mean interval between the CI studies and
PET/CT was 6 days (range 1–12 days).
T and N staging was based on the international TNM
classification, as follows: pT1, tumor invading submuco-
sal layer; pT2, tumor invading muscularis propria or
subserosa; pT3, tumor penetrating serosa and perivisc-
eral fat; and pT4, tumor invading adjacent organs.
Lymph nodes were likewise classified: N0, no regional
lymph node metastasis; N1, metastasis in one to three
perirectal lymph nodes; N2, metastasis in four or more
perirectal lymph nodes; and N3, metastasis in pelvic
lymph nodes.
The PET/CT scan analysis for liver metastases was
based on apparently visualized activity greater than nor-
mal liver parenchyma. Abnormalities where the FDG up-
take was less than the physiological liver uptake were
not considered to be positive. For chest activity, the focal
uptake of FDG needed to be greater than the mediastinal
uptake and needed to correspond to an anatomic struc-
ture or abnormality seen by the CI studies.
A single radiologist with 5 years of experience in
abdomino-pelvic MDCT and MRI evaluated the images.
All patients with CRC were staged according to the tu-
mor/node/metastasis (TNM) classification described by
the American Joint Committee on Cancer (AJCC) for
CRC [10]. The PET/CT findings were directly correlated
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down-staging and change in management were evaluated.
Results of the CI studies were regarded as the standard
reference point for PET/CT. Sensitivity, specificity, posi-
tive predictive value, negative predictive value and accu-
racy of PET/CT were calculated for T and N staging
considering the results of CI studies. The correlation of
the PET/CT with the CI studies was compared by a
kappa agreement coefficient. Differences in the accuracy
for N and T staging were assessed by χ2 and related-
samples marginal homogeneity tests. SPSS 19.0 software
(Chicago, Illinois, USA) was used for statistical analysis.
The level of statistical significance with 0.95 confidence
limits was set at P = 0.05.
Results
Sixty-four consecutive patients underwent PET/CT scan-
ning. The mean age was 59 years (range 18–85 years),
and 69% were male. Thirty-nine patients had rectal can-
cer and underwent MRI, while 25 patients had colon
cancer and underwent a MDCT scan. Results of CI stud-
ies with regard to T and N features of the patients were
summarized in Table 1. It was possible to detect all pri-
mary lesions during CI studies.
The accuracy, sensitivity, specificity, positive predictive
value and negative predictive value for PET/CT assess-
ment based on the results of CI studies were calculated
separately for the T and N stages . The sensitivity and ac-
curacy of PET/CT for T staging was also higher than for
N staging (Table 2).
The κ agreement coefficient analysis showed that the
correlation between PET/CT and CI studies were higher
with the T staging than the N staging. The kappa value
for the T staging was found to be 0.604 and for N stag-
ing was 0.283. These results were statistically significant
(Table 3).
After comparison PET/CT and CI findings for the same
patients with regard to T and N stages, statistically signifi-
cant differences between PET/CT and CI studies in the T
and N stages of the same patients were found (for T
stages: χ2 = 29.93, P = 0.025; for N stages: χ2 = 42.84, P =
0.0001) (Table 3).
PET/CT accurately identified the primary tumor in all
patients. Comparing PET/CT with CI studies, there were
incidental findings in 6 (9.4%) patients. According to theTable 1 T and N staging of all colorectal cancers
T staging N staging
Localization Method T1 T2 T3 T4 N0 N1 N2 N3
Rectum (n = 39) PET/CT - 8 26 3 19 16 4 -
CI studies - 11 23 5 16 19 3 1
Colon (n = 25) PET/CT 1 6 16 2 20 5 - -
CI studies - 6 14 5 6 18 1 -PET/CT results, the preoperative stage of 14 patients
(21.9%) changed. Down staging was found in 8 patients,
while over staging was found in six patients (Table 4).
PET/CT examination revealed suspected findings for
metastasis in mediastinum in 4 patients, liver metastasis
in 1 patient, and left supraclavicular metastasis in 1 pa-
tient. However, 4 of these patients were found to be mis-
takenly over-staged in which the situation later was
confirmed by biopsies or further imaging studies. All of
the mediastinal metastases were false positive (Table 5).
Furthermore, this process caused a delay in the surgical
treatment for these patients.
Additional findings from the PET/CT changed the
treatment strategies for two patients (3.2%). PET/CT
identified a liver metastasis in one patient who could not
be shown by CI studies (Figure 1). A chemotherapy regi-
men for metastatic disease was administered to the pa-
tient for a 1.5 cm hepatic metastasis near the right
hepatic vein. In the second patient, isolated supraclavi-
cular lymph node metastasis was detected by PET/CT
(Figure 2), which changed the surgical treatment strategy
for this patient. A simultaneous supraclavicular lymph
node excision and total mesorectal excision were per-
formed in this patient.
Discussion
Surgery is the main treatment with curative potential for
recurrent and metastatic (mainly liver) colorectal cancer.
The presence of the disease at a site distant to the planned
surgery affects the type and timing of treatments. To-
gether, this wide variation in disease presentations and ex-
tents of treatment underpins the rationale for accurate
pre-operative staging. Although colonoscopy is the most
common method for detecting and diagnosing colorectal
cancers, it does not produce accurate preoperative infor-
mation regarding tumor invasion and lymph node in-
volvement. For this purpose, MDCT and MRI are used as
the standard modality for preoperative staging of colorec-
tal cancers. Moreover, neoadjuvant therapies are per-
formed for stage II and stage III rectal cancer. It has been
shown that neoadjuvant therapy decreases local recur-
rence and increases survival [11]. Therefore, correct pre-
operative staging has a critical role in determining
whether patients should undergo neoadjuvant therapy.
Similarly, preoperative neoadjuvant strategies for colonic
cancers are dependent on the staging accuracy of CT [12].
Unfortunately, CT cannot provide complete correct stag-
ing of colorectal cancer, even though an improvement in
the resolution has recently been achieved with MDCT.
Use of MDCT on determination of T and N staging
has variable results [5,13-16]. Although it has been
reported up to 86% of accuracy for T staging, this rate
has been decreased to 59% for N staging. Lack attenua-
tion differences between tumor and normal visceral softy
Table 2 Evaluation of the efficacy of PET/CT for T and N staging
Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%) Accuracy (%)
T staging 95.74 75 91.83 85.71 90.47
N staging 52.38 85 88 47.36 63.49
Table 4 Changing pattern in patients’ stage as determined
by PET/CT
Change of stage Patients (%)
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thought to be responsible for low sensitivity and speci-
ficity of MDCT for T staging [17]. MDCT can be consid-
ered to be more efficacious for N staging than T staging.
However, efficacy of MDCT on determination of lymph
node status of CRC has not been showed by many stud-
ies. Due to heterogeneity on the design of the studies
and technical differences, it has been impossible to get
generally accepted results.
Likewise, MRI offers an 81% overall accuracy com-
pared with histological findings for T and N staging [6].
Due to these imperfect results of CI studies, authors
have investigated new preoperative imaging modalities
for colorectal cancer; some authors suggest the use of
PET/CT as an alternative option [15,18,19]. It has been
shown that the accuracy of PET/CT can be as high as
94.3% for T staging. However, sensitivity and specificity
for N staging still remains to be low in comparison to T
staging [20]. Positive lymph nodes that are smaller than
1 cm may be the major source for being missed by PET/
CT [18]. In this study, it has been shown that PET/CT
has the accuracy rate of 90.47% for T staging. Although
it can be regarded as an acceptable rate for T staging,
lack of both pathological confirmation and comparison
with CI studies attenuate the reliability of our results.
In addition to provide accurate staging, the ability of
PET/CT to detect metastatic disease is thought to be a
critical point for its potential therapeutic impact. How-
ever, studies have reported inconsistent findings about
the effect of PET/CT on clinical practice and surgical
management. Some studies found no effect and others
reported decreased morbidity from improved surgical
techniques arising from increased precision in tissue
identification. In some studies, PET/CT was compared
directly with CT alone, which is one example of a falsely
enhanced apparent therapeutic impact for PET/CT.
PET/CT has commonly been performed for the detection
of recurrence or for routine follow-up in patients with co-
lorectal cancer. The sensitivity and specificity of PET/CT
in patients with recurrent colorectal cancer was found to
be 97% and 76%, respectively [14]. However, PET imaging
provides insufficient anatomical information; this lack ofTable 3 Correlation of PET/CT with CI studies
Kappa value p value
T staging 0.604 <0.001
N staging 0.283 0.002information was improved with the integration of CT into
PET imaging. Cohade et al. showed that the accuracy of
PET alone and PET/CT in preoperative staging of colorec-
tal cancer was 78% and 89%, respectively [14]. MRI also
provides additional accuracy to liver contrast-enhanced
CT in the assessment of a patient’s suitability for hepatic
resection.
There are limited studies in the literature that have in-
vestigated PET/CT in the preoperative staging of colo-
rectal cancer. By using PET/CT as a preoperative
imaging modality, it was reported that the stages of the
tumors were changed in 27% to 39% of the patients ei-
ther down- or over-stages [21-24]. Our data showed that
the preoperative stage changed in 21.9% of the cases
according to the PET/CT results; this result is compara-
ble to findings in the literature. However, a modification
of clinical management including only the surgical treat-
ment modality was found in only 3.2% of the cases. In
eight and six cases, there were down and over staging of
the primary tumor which have no effect on the choice of
surgical treatment, respectively. Any modifications with
regard to postoperative adjuvant treatment caused by
preoperative PET/CT were beyond the primary aim of
this study, which was to evaluate the effect of PET/CT
on surgical treatment. It has been reported that use of
PET/CT in staging of rectal cancer resulted in discor-
dant and incidental findings in an almost half of the
cases. Although PET/CT brought on stage migration in
30% of the cases, either down or over staging, potential
management changes occurred only in 25% and there
was no need to change the surgical management [25].
This discordance may be explained by a high false posi-
tivity rate of PET/CT for detecting distant metastasis.
PET/CT detected 6 distant metastases, which could not
be shown by CI studies. Four of the 6 distant metastases
were verified as false positive by biopsies (Table 5). The
high rate of false positive results which was caused by
the high accumulation of FDG in mediastinal lymphDown-staging Stage-III→ Stage-II 3 (4.7)
Stage-II→ Stage-I 5 (7.8)
Over-staging Stage-II→ Stage-IV 2 (3.1)
Stage-III→ Stage-IV 4 (6.2)
Total 14 (21.8)







Liver 1 Not confirmed histologically
Left supraclavicular
lymph node
1 Excision and pathological
examination
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dence of chronic infectious and inflammatory diseases of
the chest in our country. The present study suggests that
some additional evidence offered by PET/CT was not al-
ways beneficial and caused preoperative diagnostic di-
lemmas, which caused further invasive examinations,
additional costs and a delay of the disease management.
Selecting patients with locally advanced tumors in whom
distant metastases are more expected and patients with
suspected metastasis detected with other imaging mo-
dalities for PET/CT scanning may be more beneficial
and practical for clinical use.
Local staging of colorectal cancer mostly depends on
CI studies. There are various studies regarding CT and
MRI that reported a high success rate. The specificity
and sensitivity of CT and MRI for the detection of adja-
cent organ invasion were reported as comparable [26].
PET/CT is inappropriate to determine the exact depth
of invasion of the primary tumor due to its limited reso-
lution. However, PET/CT may be appropriate in selected
cases to estimate penetration and local invasion. MDCT
provides more accurate anatomical and structural infor-
mation than PET. Therefore, T staging of colorectalFigure 1 Appearance of primary tumor and hepatic metastases in PEcancer by PET/CT is almost completely reliant on CT.
As expected, the present study demonstrated a close
correlation of PET/CT with CI studies in T staging
(Tables 1 and 3).
The main problem of staging of colorectal cancer is
the prediction of lymph node involvement. The sensi-
tivity of CT for the detection of lymph node involve-
ment has been reported to be between 29% and 90% for
CRC [13,25]. PET/CT showed low sensitivity (52%) and
relatively high specificity (85%) for detecting lymph
node involvement in the present study. The overall ac-
curacy of PET/CT (63%) was below the expected value.
Several previous studies have reported a comparable
rate of lymph node involvement detection by PET/CT,
reporting low sensitivity (29–37%) and high specificity
(83–96%) [25,27,28].
A full assessment of the colon is mandatory to localize
the tumor, to evaluate locoregional spreading, and to de-
pict synchronous colonic lesions. For that purpose,
MDCT is the most favored imaging technique. However,
CT might have poor performances for determining local
tumor extension in the absence of colon distension [29].
CT colonography is another exam which is primarily
used to evaluate the colon in cases of incomplete colo-
noscopy and as an alternative means of screening for co-
lorectal carcinoma [30,31]. Although both contrast
enhancement by using intravenous agents to define the
boundaries of structures, and colonography to identify
primary tumor with its local extent increases the accu-
racy of such modalities, the choice of PET/CT without
intravenous contrast medium or colonography has beenT/CT image.
Figure 2 Appearance of primary tumor and left supraclavicular lymph node metastases in PET/CT image.
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[18]. Moreover, contrast-enhancement causes more ac-
curate N staging of rectal cancer compared with non-
contrast-enhancement during PET/CT examination.
PET/CT colonography is also used in preoperative diag-
nosis of the tumors proximal to obstructive colorectal
cancers, which were defined as cancers that cannot be
traversed colonoscopically [32]. Use of this technique
has been reported to have an overall accuracy of 80%
and 60% for the evaluation of tumor depth and lymph
nodes, respectively. Use of water enema or air-contrast
enema during CT colonography may also result in better
evaluation of the local spread for T staging for CRC
[31,33]. However, FDG as a radiotracer may play the role
of “metabolic contrast agent”. By that way, it can be
helpful to increase the contrast resolution of the struc-
tures, to characterize the perilesional tissues and to com-
pensate for the absence of luminal distension on the
unenhanced CT images [18]. Therefore, identification of
the primary tumor with its local extent by using FDG
PET/CT, without administration of intravenous contrast
medium or colonography can be possible as supported
by our results.
The high false-negative rate of PET/CT may be attrib-
utable to the limited resolution and proximity of the in-
volved lymph nodes to the locally advanced primary
tumor or the urinary bladder. In addition, while a lymph
node with a micro-metastasis and a diameter >5 mm
can be considered to be involved by CT assessment, the
same lymph node can be considered as non-metastatic
by PET/CT because no FDG uptake is detected. These
results imply that preoperative PET/CT is of limited
value for detecting metastasis to regional lymph nodes.
There were four suspected pulmonary and one supra-
clavicular metastasis in our patients. Although chest CT
before PET/CT could help to differentiate the malignant
potential of such lesions, use of chest CT in staging ofCRC remains controversial [17,34]. It was shown that
chest CT altered the initial TNM stage in less than 1%
of CRC patients. In addition, indeterminate lung nodules
were found to be positive in almost one quarter of the
patients [34]. In the light of these findings, chest CT was
not used as the primary staging method in this study.
The main limitation of our study was the wide variety
of pathological groups and subgroups of the primary tu-
mors that may have influenced the sensitivity and accu-
racy of PET/CT for TNM staging of colorectal cancer, as
FDG uptake may differ among tumor types. Although
the contribution of PET/CT to the detection of recur-
rent and metastatic colorectal cancer has been reported
in many current studies, its value in staging the primary
disease has not been well-defined and usually is not
recommended as a first-line diagnostic tool in clinical
practice. Although most of the tumors presented in this
study had T staging of T2 and T3, and N staging of N0
and N1, it could be difficult to generalize the results to
all subgroups of colorectal cancers. In addition, presence
of both colonic and rectal cancers, and application of
the neo-adjuvant treatment to Stage II and III rectal can-
cers might be the other confounding variables to affect
the reliability of our results. Therefore, more studies that
include special subgroups of colon and rectal cancers
are necessary to determine the role of PET/CT in pri-
mary staging.
PET/CT seems to be a useful tool in the evaluation of
colorectal cancer by allowing to metabolically character-
izing undetermined lesions suspected for recurrence of
disease, to perform a complete pre-surgical staging and
to identify occult metastatic disease. However since it is
an expensive modality and the impact to the manage-
ment of disease may be low as in our study; its use in
routine preoperative examination is controversial.
Another aspect to be considered for the routine use of
PET/CT as a first-line diagnostic modality is contrast-
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routine contrast-enhanced CT imaging; this method will
allow for whole body detection of distant metastases and
show the primary tumor and loco-regional lymph nodes
more accurately. Studies with contrast-enhanced PET/
CT scans are needed in the future.
Conclusions
The use of PET/CT for preoperative staging did not impact
the clinical management of 96.8% of our patients. The pres-
ent study revealed that PET/CT does not provide higher di-
agnostic precision to CI modalities in the detection of
primary tumors, lymph node involvement or distant metas-
tases. These results suggest that PET/CT should not be
routinely used for primary staging of colorectal cancer.
More studies are required to select the patients who might
benefit from PET/CT during initial staging.
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